Role of Uric Acid Albumin Ratio in Predicting Development of Acute Kidney Injury and Mortality in Intensive Care Unit Patients

Participation by nephrologists is needed in most intensive care units, even when such units are ‘closed'. This participation should assist with diagnosis and management of intrinsic and complex renal diseases such as vasculitis, complex metabolic and electrolyte disorders including hyponatremia, and acute kidney injury (AKI) with and without underlying chronic kidney disease (CKD). Early nephrologist involvement will also facilitate transition to continuing care and follow-up after an episode of AKI, but may also assist in avoiding dialysis where treatment is futile. Management of AKI by intensivists should be in partnership with nephrologists to oversight and hopefully to minimize progression to CKD.

Download Full-text

Fenoldopam Mesylate: A Narrative Review of Its Use in Acute Kidney Injury

Current Pharmaceutical Biotechnology ◽

10.2174/1389201020666190417124711 ◽

2019 ◽

Vol 20 (5) ◽

pp. 366-375 ◽

Cited By ~ 1

Author(s):

Annalisa Noce ◽

Giulia Marrone ◽

Valentina Rovella ◽

Andrea Busca ◽

Caterina Gola ◽

...

Keyword(s):

Intensive Care Unit ◽

Acute Kidney Injury ◽

Intensive Care ◽

Kidney Injury ◽

Protective Role ◽

Small Samples ◽

Hospital Treatment ◽

Postoperative Aki ◽

Positive Results

Background: Fenoldopam mesylate is a selective agonist of DA-1 receptors. It is currently used for the in-hospital treatment of severe hypertension. DA-1 receptors have high density in renal parenchyma and for this reason, a possible reno-protective role of Fenoldopam mesylate was investigated. Method: We examined all studies regarding the role of Fenoldopam mesylate in Acute Kidney Injury (AKI); particularly, those involving post-surgical patients, intensive care unit patients and contrastinduced nephropathy. Results: Fenoldopam mesylate was found to be effective in reducing the onset of postoperative AKI, when used before the development of the kidney damage. Positive results were also obtained in the management of intensive care unit patients with AKI, although the clinical studies investigated were few and conducted on small samples. Conclusion: Conflicting results were achieved in contrast-induced nephropathy.

Download Full-text

The Role of Dexmedetomidine for the Prevention of Acute Kidney Injury in Critical Care

EMJ Nephrology ◽

10.33590/emjnephrol/21-00087 ◽

2021 ◽

pp. 97-106

Author(s):

Gion Ruegg ◽

Nora Luethi ◽

Luca Cioccari

Keyword(s):

Experimental Data ◽

Intensive Care Unit ◽

Acute Kidney Injury ◽

Clinical Trials ◽

Renal Function ◽

Critical Care ◽

Intensive Care ◽

Kidney Injury ◽

Ischaemia Reperfusion

Acute kidney injury (AKI) occurs in up to 50% of patients admitted to the intensive care unit and is associated with increased mortality. Currently, there is no effective pharmacotherapy for prevention or treatment of AKI. In animal models of sepsis and ischaemia-reperfusion, α2-agonists like dexmedetomidine (DEX) exhibit anti-inflammatory properties and experimental data indicate a potential protective effect of DEX on renal function. However, clinical trials have yielded inconsistent results in critically ill patients. This review discusses the pathophysiological mechanisms involved in AKI, the renal effects of DEX in various intensive care unit-related conditions, and summarises the available literature addressing the use of DEX for the prevention of AKI.

Download Full-text